Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas (SOLAR)

• Status: RECRUITING
• Trial end date: 2030-11-01

Summary

The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.

• Phase: PHASE1

Details

• Lead Sponsor: University of Utah
• Collaborator: ADC Therapeutics S.A.
• Treatments: loncastuximab tesirine; Rituximab